PE20151434A1 - Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociados con el mismo - Google Patents

Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociados con el mismo

Info

Publication number
PE20151434A1
PE20151434A1 PE2015000538A PE2015000538A PE20151434A1 PE 20151434 A1 PE20151434 A1 PE 20151434A1 PE 2015000538 A PE2015000538 A PE 2015000538A PE 2015000538 A PE2015000538 A PE 2015000538A PE 20151434 A1 PE20151434 A1 PE 20151434A1
Authority
PE
Peru
Prior art keywords
methods
heart failure
reduction
reduce
risks
Prior art date
Application number
PE2015000538A
Other languages
English (en)
Spanish (es)
Inventor
D Travis Wilson
Hani N Sabbah
Original Assignee
Stealth Peptides Int Inc
Henry Ford Health Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides Int Inc, Henry Ford Health Systems filed Critical Stealth Peptides Int Inc
Publication of PE20151434A1 publication Critical patent/PE20151434A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Emergency Medicine (AREA)
PE2015000538A 2012-10-22 2013-10-22 Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociados con el mismo PE20151434A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261716867P 2012-10-22 2012-10-22
US201361822752P 2013-05-13 2013-05-13
US201361839743P 2013-06-26 2013-06-26
US201361839750P 2013-06-26 2013-06-26

Publications (1)

Publication Number Publication Date
PE20151434A1 true PE20151434A1 (es) 2015-10-16

Family

ID=50545459

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000538A PE20151434A1 (es) 2012-10-22 2013-10-22 Metodos para la reduccion de los riesgos asociados con el insuficiencia cardiaca y factores asociados con el mismo

Country Status (13)

Country Link
US (4) US20150246092A1 (enExample)
EP (5) EP4397314B1 (enExample)
JP (3) JP2016503397A (enExample)
KR (1) KR20160009008A (enExample)
CN (2) CN110193077A (enExample)
AU (2) AU2013334788A1 (enExample)
BR (1) BR112015009072A2 (enExample)
CA (1) CA2889155A1 (enExample)
ES (1) ES3058737T3 (enExample)
MX (1) MX2015005102A (enExample)
NI (1) NI201500057A (enExample)
PE (1) PE20151434A1 (enExample)
WO (1) WO2014066419A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3626252A1 (en) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
US10793597B2 (en) 2013-03-01 2020-10-06 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial diseases associated with a mutation in SURF 1 or POLG gene resulting in a disruption of mitochondrial oxidative phosphorylation
US10047395B2 (en) * 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US10870678B2 (en) 2016-04-11 2020-12-22 Arcuate Therapeutics, Inc. Chiral peptides
EP3474877A4 (en) * 2016-06-24 2019-11-27 University of Southern California MENTSH ANALOGUE AS THERAPEUTICS FOR DIABETES, ADIPOSITAS AND ASSOCIATED DISEASES AND COMPLICATIONS THEREOF
JP7630906B2 (ja) 2017-02-01 2025-02-18 イェール・ユニヴァーシティー 利尿薬耐性の治療
SG11202006157VA (en) 2018-01-05 2020-07-29 Corvidia Therapeutics Inc Methods for treating il-6 mediated inflammation without immunosuppression
KR102546547B1 (ko) 2018-01-11 2023-06-22 삼성전자주식회사 보행 보조 방법 및 장치
KR20220052561A (ko) 2020-10-21 2022-04-28 장영진 어류 가공물 및/또는 콩 가공물을 유효성분으로 포함하는 심부전의 예방 또는 치료용 약학 조성물
CN120329388B (zh) * 2025-04-30 2025-09-26 中日友好医院(中日友好临床医学研究所) 一种双靶点多肽及其在心衰治疗中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US20040131614A1 (en) * 2002-07-19 2004-07-08 Abbott Biotechnology Ltd. Treatment of pulmonary disorders using TNFalpha inhibitor
SI2656854T1 (sl) * 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
EP1890153A1 (en) * 2006-08-16 2008-02-20 F. Hoffman-la Roche AG Cardiac troponin as an indicator of advanced coronary artery disease
EP1890154B1 (en) * 2006-08-16 2012-07-04 F. Hoffmann-La Roche AG Cardiac troponin as an indicator of advanced coronary artery disease
US20080318909A1 (en) * 2007-06-14 2008-12-25 Sparagna Genevieve C Use Of Linoleic Compounds Against Heart Failure
CN107802821A (zh) * 2008-02-26 2018-03-16 康奈尔大学 用于防止和治疗急性肾损伤的方法
CA2770688C (en) * 2009-08-12 2018-06-05 Cornell University Methods for preventing or treating metabolic syndrome
EP3603658B1 (en) * 2009-10-05 2025-01-08 Cornell University Peptide for use in the treatment of heart failure resulting from hypertrophic cardiomyopathy
EP2504032A4 (en) * 2009-11-24 2013-06-19 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR PREVENTING OR TREATING THROMBOSIS
EP2519249A4 (en) * 2009-12-31 2013-06-26 Stealth Peptides Int Inc METHOD FOR CARRYING OUT A CORONARY ARTERY BYPASS PROCEDURE
US20130195837A1 (en) * 2009-12-31 2013-08-01 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
EP3332795A1 (en) * 2010-02-26 2018-06-13 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP2808029A3 (en) * 2010-03-15 2015-04-01 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
US10188693B2 (en) * 2012-08-02 2019-01-29 Stealth Biotherapeutics Corp Methods for treatment of atherosclerosis
HK1215934A1 (zh) * 2012-12-06 2016-09-30 Stealth Peptides International, Inc. 肽治疗剂及其使用方法
CA2916497C (en) * 2013-06-26 2022-07-12 Stealth Biotherapeutics Corp Methods for the regulation of matrix metalloproteinase expression
US10047395B2 (en) * 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions

Also Published As

Publication number Publication date
JP2016503397A (ja) 2016-02-04
EP4397314B1 (en) 2025-12-03
US20230190859A1 (en) 2023-06-22
KR20160009008A (ko) 2016-01-25
HK1213799A1 (en) 2016-07-15
NI201500057A (es) 2015-07-16
EP4397314A1 (en) 2024-07-10
JP2018109012A (ja) 2018-07-12
US20150246092A1 (en) 2015-09-03
CA2889155A1 (en) 2014-05-01
ES3058737T3 (en) 2026-03-12
US20200360462A1 (en) 2020-11-19
EP3586862A1 (en) 2020-01-01
EP3586862B1 (en) 2021-12-08
EP4005582A1 (en) 2022-06-01
US20250255929A1 (en) 2025-08-14
CN110193077A (zh) 2019-09-03
EP2908839A2 (en) 2015-08-26
EP4711005A3 (en) 2026-04-22
MX2015005102A (es) 2016-02-09
EP2908839A4 (en) 2016-06-15
WO2014066419A2 (en) 2014-05-01
AU2013334788A1 (en) 2015-06-04
WO2014066419A3 (en) 2014-06-12
EP4711005A2 (en) 2026-03-18
AU2018206766A1 (en) 2018-08-09
CN105050613A (zh) 2015-11-11
JP2019194193A (ja) 2019-11-07
EP2908839B1 (en) 2019-08-21
BR112015009072A2 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
NI201500057A (es) Métodos para reducir riesgos asociados con insuficiencia cardiaca y factores asociados
UY39119A (es) Proteínas de fusión para tratar trastornos metabólicos
GT201400166A (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
DOP2017000097A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
UY36370A (es) Polipéptidos fgf-21 modificados y sus usos
MX359201B (es) Polipeptidos que se unen al complemento humano 5 (c5).
ES2694667T3 (es) Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato
MX2021014242A (es) Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora.
AR083878A1 (es) Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
EA201491934A1 (ru) Аналоги глюкагоноподобного пептида-2 (glp-2)
NI201300143A (es) Coagonista del receptor de glucagón/glp-1
CL2008003476A1 (es) Variante del peptido natriuretico de tipo c (cnp); composicion farmaceutica que la comprende; y su uso para tratar una displasia del esqueleto o un trastorno de la musculatura lisa vascular.
CL2015003199A1 (es) Peptidos terapeuticos
MX2016004441A (es) Tratamiento del cancer con una combinacion de plinabulina y taxano.
CL2016003075A1 (es) Composición para tratar diabetes, que contiene un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
MX2018007933A (es) Metodo de tratamiento de mamifero, incluido el ser humano, contra cancer usando agotamiento de metionina y asparagina.
MX2017005186A (es) Celulas madre neurales estables que comprenden un polinucleótido exógeno que codifica un factor de crecimiento y métodos de uso de las mismas.
GT201500168A (es) Polipéptidos estabilizados del factor de crecimiento tipo insulina
NI201200085A (es) Método para tratar la insuficiencia cardíaca con péptidos tipo estrescopina
MX389091B (es) Tratamiento de pacientes con diabetes mellitus de tipo 2.
CL2017001843A1 (es) Lixisenatida y/o una sal farmacéuticamente aceptable de la misma para el tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2.
CO2019003865A2 (es) Proteína terapéutica
BR112016028561A2 (pt) composição, forma de dosagem, e, métodos para reduzir o risco para mortalidade em um indivíduo, o risco para uma doença ou condição em um indivíduo, triglicerídeos em um sangue de indivíduo, a frequência cardíaca em repouso de um indivíduo, o colesterol de lipoproteína de densidade não alta em um indivíduo, o colesterol total em um indivíduo, a apolipoproteína b em um sangue de indivíduo, pressão sanguínea sistólica em um indivíduo e a pressão sanguínea diastólica em um indivíduo, para prolongar a vida de um indivíduo, para tratar hipertrigliceridemia em um indivíduo e para aumentar um índice de ômega-3 em células vermelhas do sangue de um indivíduo.
CY1120861T1 (el) Συνθεσεις και μεθοδοι για θεραπευτικη αγωγη διαβητη τυπου 1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal